香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Zhaoke Ophthalmology Limited 兆科眼科有限公司 授出購股權事宜的詳情 下 文 載 列 授 出 購 股 權 事 宜 的 詳 情： 授 出 日 期： 2025年9月5日 （於英屬處女群島註冊成立並於開曼群島存續的有限公司） （股份代號：6622） 授出購股權 茲提述本公司日期為2021年4月16日 的 招 股 章 程，內 容 有 關 於2021年4月1日採納 的 首 次 公 開 發 售 後 購 股 權 計 劃 的 主 要 條 款。 本公告乃根據上市規則第17.06A條 作 出。董 事 會 欣 然 公 佈，於2025年9月5日，本 公司向97名承授人授出合共8,000,000份 購 股 權，有 待 承 授 人 接 納，並 須 符 合 上 市 規 則 及 首 次 公 開 發 售 後 購 股 權 計 劃 條 款。 於合共8,000 ...

| 截至月份: | 2025年8月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 兆科眼科有限公司 | | | 呈交日期: | 2025年9月2日 | | | I. 法定/註冊股本變動 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06622 | 說明 | 兆科眼科有限公司 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,600,000,000,000 | USD | 0.00000025 | USD | | 400,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,600,000,000,000 | USD | 0.00000025 | USD | ...

Summary of Zhaoke Ophthalmology Conference Call Company Overview - **Company**: Zhaoke Ophthalmology - **Core Products**: TAB014 (Bevacizumab biosimilar), Cyclosporine eye gel, Low-concentration Atropine eye drops Key Industry Insights - **Product Approval Timeline**: - TAB014, Cyclosporine eye gel, and low-concentration Atropine are expected to be approved between Q2 and Q3 of 2026, significantly enhancing the company's profitability [2][3] - Two specifications of Atropine sulfate (0.01% and 0.02%) have been submitted for approval, with 0.01% already passing the National Medical Products Administration's (NMPA) inspection [2][8] Core Product Developments - **Low-concentration Atropine**: - Expected approval in H1 2026, with clinical data showing effectiveness in delaying myopia progression [2][9] - **Cyclosporine Eye Gel**: - Resubmitted for approval based on existing Phase III data, with a significant reduction in dosage frequency and concentration [2][10] - **Bevacizumab Injection (TMB 014)**: - First in China for age-related macular degeneration, completed Phase III studies, and received acceptance from CDE [2][12] Market Expansion and Collaborations - **International Partnerships**: - Collaborations established in the Middle East, Southeast Asia, East Asia (e.g., South Korea), and Australia, enhancing revenue sources [4][25] - Partnerships with U.S. and French companies for product development and production under CDMO model [4][6] Production and Quality Assurance - **Production Capacity**: - Five production lines in Nansha, compliant with CMC standards, capable of producing 100 million single doses [21][22] - **Quality System**: - Strong emphasis on production quality, leading to successful collaborations with international firms [6][21] Early and Mid-stage Product Pipeline - **Additional Products**: - Ongoing development of various mid-stage products, including a drug for presbyopia and a small molecule peptide for corneal epithelial defects [7][15] Sales and Marketing Strategy - **Sales Team Optimization**: - A professional sales team established to enhance hospital coverage and brand recognition [24][30] - **Multi-channel Strategy**: - Plans to utilize e-commerce and optical centers for product distribution, particularly for Atropine [28][34] Financial Position - **Cash Reserves**: - As of June 30, 2025, the company holds over RMB 1 billion in cash and cash equivalents, supporting future innovation and commercialization efforts [26] Future Focus Areas - **Product Launch Preparations**: - Ensuring smooth registration and market entry for three major products, while enhancing existing sales team efficiency [30][27] - **Brand Building**: - Collaborations with key opinion leaders and clinical studies to enhance brand influence, particularly for Atropine [29][35] Conclusion - Zhaoke Ophthalmology is positioned for significant growth with a robust pipeline of products, strategic international partnerships, and a strong focus on quality and market expansion. The company aims to leverage its production capabilities and sales strategies to enhance its market presence and profitability in the ophthalmology sector.

Core Insights - The company, Zhaoke Ophthalmology (6622.HK), has three core drug candidates that have entered the New Drug Application (NDA) stage, with expected approvals in China in the second and third quarters of next year [1] - The two formulations of atropine eye drops at concentrations of 0.01% and 0.02% are aimed at controlling the progression of myopia in adolescents [1] - Zhaoke's 0.01% atropine eye drops, branded as "Mei Le Tong," is the second product in the industry to receive an application acceptance, following the approval of a similar product by competitor Xingqi Eye Pharmaceutical last March [1] Product Comparison - Zhaoke's COO, Dai Xiangrong, noted that their product has a pH value close to 6, making it more neutral and less irritating compared to the competitor's product [1] - The industry estimates that Xingqi's 0.01% atropine eye drops generated sales of over 700 million RMB within nine months of its launch [1] - Although Zhaoke did not provide a specific sales target for its 0.01% atropine eye drops, it indicated that it would use the competitor's sales as a benchmark [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) reported a significant decline in revenue and an increase in net loss, while advancing its drug candidates towards commercialization [1] Financial Performance - The company achieved revenue of HKD 15.803 million, a year-on-year decrease of 68.25% [1] - The net loss amounted to HKD 117 million, representing a year-on-year increase of 53.85% [1] Drug Development Progress - Three core drug candidates, including Atropine Sulfate Eye Drops, Cyclosporine Eye Gel, and Bevacizumab Vitreous Injection, have entered the New Drug Application (NDA) stage, with a goal of commercializing 12 drugs by the end of 2026 [1] Strategic Partnerships - Zhaoke Ophthalmology signed a distribution and supply agreement with PT Ferron Par Pharmaceuticals for its Atropine Sulfate Eye Drops in Indonesia, granting exclusive rights for import, promotion, distribution, marketing, and sales [1] - The agreement includes an upfront payment and potential milestone payments based on certain achievements [1]

Core Viewpoint - Zhaoke Ophthalmology (06622) reported a significant decline in revenue and an increase in net loss, while advancing its drug candidates towards commercialization [1] Financial Performance - The company achieved revenue of 15.803 million HKD, a year-on-year decrease of 68.25% [1] - Net loss amounted to 117 million HKD, reflecting a year-on-year increase of 53.85% [1] Drug Development Progress - Three core drug candidates, including Atropine Sulfate Eye Drops, Cyclosporine Eye Gel, and Bevacizumab Vitreous Injection, have entered the New Drug Application (NDA) stage, with a goal of commercializing a total of 12 drugs by the end of 2026 [1] Strategic Partnerships - The company signed a distribution and supply agreement with Indonesia's leading pharmaceutical company, PT Ferron Par Pharmaceuticals, for its core product, Atropine Sulfate Eye Drops (NVK002) [1] - Under the agreement, Zhaoke Ophthalmology grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia, along with receiving an upfront payment and potential milestone payments based on achievements [1]

今年，港股创新药势不可挡，成为资本市场的重磅热点。 数据最具说服力，港股创新药概念指数从年初至今涨幅已超100%，不仅大幅跑赢恒生指数，更以扎实 的上涨态势重塑了市场对创新药产业的信心。 这轮行情的背后并非偶然，机构普遍认为，其核心驱动力是政策、基本面、资金面的三重共振，而非短 期利好的临时拉动。譬如，7月国家医保局首次将具备高临床价值但暂未纳入医保的创新药纳入商保支 付范围，为创新药开辟了更多元的变现路径；产业端的出海进程也取得历史性突破，大额BD合作频频 落地，整个创新药产业的活力正加速释放。 在行业整体向好的背景下，基金经理对下半年行情的预判也更为积极，更明确指出当前正是中长期布局 创新药板块的重要窗口期。例如，永赢医药创新智选基金经理储可凡与单林便一致认为，创新药是当前 医药领域确定性最强、置信度最高、增长空间最大的核心板块。随着国内企业持续产出优秀临床数据， 叠加出海能力不断强化，未来商业化兑现路径将愈发清晰，业绩落地节奏也会逐步加快，长期成长逻辑 坚实。 正是在这样的产业红利期，近日，眼科创新药企兆科眼科发布2025年中期财报，阿托品滴眼液、环孢素 A眼凝胶、贝伐单抗注射液三大重磅眼药均已提交上市 ...

Core Viewpoint - The company, Zhaoke Ophthalmology (06622.HK), has seen its stock price nearly double this year, making it one of the top performers in the Hong Kong biotech sector, despite reporting a loss of 117 million yuan in the first half of the year due to strategic adjustments and increased R&D spending [1][2][3]. Financial Performance - Zhaoke Ophthalmology reported a loss of 117 million yuan in the first half of the year, attributed to a shift in sales strategy focusing on top-tier hospitals and optimizing the sales team, which led to a temporary decline in generic drug sales [2]. - The company's R&D expenditure for the first half of the year was 113 million yuan, an increase compared to the same period last year [3]. Product Pipeline and Market Potential - The company aims to commercialize a total of 12 drugs by the end of 2026, with a focus on core products such as atropine sulfate eye drops, cyclosporine eye gel, and bevacizumab intravitreal injection, which are currently at the application stage for market approval [3][4]. - The demand for pediatric myopia prevention is significant, with many hospitals still using in-house formulations of atropine, indicating a substantial growth opportunity in the atropine market as approved products replace these formulations [4]. Industry Trends - The incidence of eye diseases in China is rising due to factors such as aging population, increased work and study pressure, and excessive use of electronic devices. The overall myopia rate among children and adolescents was reported at 51.9% in 2022, with varying rates across different age groups [3].

Core Viewpoint - Zhaoke Ophthalmology-B (06622) reported a significant decline in revenue and an increase in net loss for the first half of 2025, leading to a drop in stock price by over 8% [1] Financial Performance - The company achieved revenue of 15.803 million HKD, representing a year-on-year decrease of 68.25% [1] - The net loss amounted to 117 million HKD, which is an increase of 53.85% compared to the previous period [1] Reasons for Financial Changes - The increase in net loss is primarily attributed to the absence of one-time licensing income recognized in the previous period under a product licensing agreement [1] - Increased R&D expenses due to the initiation of Phase I and II clinical trials for BRIMOCHOL™ PF and CARBACHOL™ PF, as well as a new Phase III clinical trial for cyclosporine eye gel, offset the impact of a continuous reduction in administrative expenses during the reporting period [1]

Performance Highlights - The company reported cash and cash equivalents of 1.051 billion [4] - Significant progress in core pipeline with the acceptance of NDA for both 0.01% and 0.02% concentrations of Atropine (NVK002) for myopia in children by the National Medical Products Administration [4][21] - The company is the only one in China with two specifications of Atropine under review [19] Product Pipeline - The company has initiated clinical trials for the new drug application (NDA) of Cyclosporine eye gel for dry eye syndrome, which has been accepted by the regulatory authority [5] - The company has received FDA approval for the Phase III clinical trial application for the same product in the U.S. [5] - The company is advancing its product pipeline with several candidates including BRIMOCHOL™ PF for presbyopia and TAB014 for wet age-related macular degeneration (wAMD) [40][36] Market Expansion - The company is expanding its overseas presence and has established partnerships for drug production and supply in various regions including Australia, New Zealand, and Southeast Asia [60] - The company has covered over 1,200 hospitals across 30 provinces in China, including major eye hospitals [57] - The company is leveraging e-commerce platforms such as Tmall and JD for product distribution [58] Research and Development - The company is focusing on innovative drug formulations and delivery methods to improve patient compliance and reduce treatment burden [47][49] - The company has a comprehensive clinical data set supporting its product candidates, enhancing its competitive advantage in the market [22][29] - The company is preparing for IND submissions for several candidates, including PAN-90806 for wAMD and diabetic macular edema [50][46]